Shanxi C&Y Pharmaceutical Group Co (SZSE:300254) Piotroski F-Score: 5 (As of Aug. 25, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:300254 Shanxi C&Y Pharmaceutical Group Co Ltd SZSE:300254
47 GF Score
Price ¥9.32
GF Value ¥12.40
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Shanxi C&Y Pharmaceutical Group Co Piotroski F-Score?

Shanxi C&Y Pharmaceutical Group Co SZSE:300254 +0.76% 47 Piotroski F-Score is 5 as of Aug. 25, 2026, which is at its 10-year median of 5.00. GuruFocus rates SZSE:300254 with a GF Score™ of 47/100 and a GF Value™ of ¥12.40 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 983 Drug Manufacturers companies, Shanxi C&Y Pharmaceutical Group Co ranks better than 60.33% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shanxi C&Y Pharmaceutical Group Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Shanxi C&Y Pharmaceutical Group Co's Piotroski F-Score or its related term are showing as below:

SZSE:300254' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 8
Current: 5

During the past 13 years, the highest Piotroski F-Score of Shanxi C&Y Pharmaceutical Group Co was 8. The lowest was 2. And the median was 5.

Shanxi C&Y Pharmaceutical Group Co  (SZSE:300254) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Shanxi C&Y Pharmaceutical Group Co Piotroski F-Score Related Terms


Shanxi C&Y Pharmaceutical Group Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Shanxi C&Y Pharmaceutical Group Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanxi C&Y Pharmaceutical Group Co Piotroski F-Score Chart

Shanxi C&Y Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 4.00 6.00 5.00 5.00

Shanxi C&Y Pharmaceutical Group Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 5.00 5.00 0.00

SZSE:300254 vs ZTS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shanxi C&Y Pharmaceutical Group Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanxi C&Y Pharmaceutical Group Co Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanxi C&Y Pharmaceutical Group Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Shanxi C&Y Pharmaceutical Group Co's Piotroski F-Score falls into.


SZSE:300254
47GF Score
Shanxi C&Y Pharmaceutical Group Co Ltd SZSE:300254
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Net Income was 21.947 + 2.523 + 3.342 + 0.944 = ¥28.8 Mil.
Cash Flow from Operations was 52.928 + 21.356 + 21.103 + 59.971 = ¥155.4 Mil.
Revenue was 238.477 + 259.313 + 173.801 + 178.084 = ¥849.7 Mil.
Gross Profit was 157.344 + 172.642 + 116.404 + 117.256 = ¥563.6 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(1496.381 + 1549.765 + 1642.59 + 1588.42 + 1528.728) / 5 = ¥1561.1768 Mil.
Total Assets at the begining of this year (Jun25) was ¥1,496.4 Mil.
Long-Term Debt & Capital Lease Obligation was ¥270.2 Mil.
Total Current Assets was ¥518.3 Mil.
Total Current Liabilities was ¥519.8 Mil.
Net Income was 10.651 + -1.963 + 10.39 + -10.01 = ¥9.1 Mil.

Revenue was 207.703 + 237.791 + 181.736 + 191.26 = ¥818.5 Mil.
Gross Profit was 140.404 + 158.609 + 126.323 + 130.44 = ¥555.8 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(1505.502 + 1527.073 + 1547.725 + 1483.632 + 1496.381) / 5 = ¥1512.0626 Mil.
Total Assets at the begining of last year (Jun24) was ¥1,505.5 Mil.
Long-Term Debt & Capital Lease Obligation was ¥194.3 Mil.
Total Current Assets was ¥456.4 Mil.
Total Current Liabilities was ¥487.0 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shanxi C&Y Pharmaceutical Group Co's current Net Income (TTM) was 28.8. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shanxi C&Y Pharmaceutical Group Co's current Cash Flow from Operations (TTM) was 155.4. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun25)
=28.756/1496.381
=0.01921703

ROA (Last Year)=Net Income/Total Assets (Jun24)
=9.068/1505.502
=0.00602324

Shanxi C&Y Pharmaceutical Group Co's return on assets of this year was 0.01921703. Shanxi C&Y Pharmaceutical Group Co's return on assets of last year was 0.00602324. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Shanxi C&Y Pharmaceutical Group Co's current Net Income (TTM) was 28.8. Shanxi C&Y Pharmaceutical Group Co's current Cash Flow from Operations (TTM) was 155.4. ==> 155.4 > 28.8 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun25 to Jun26
=270.201/1561.1768
=0.17307521

Gearing (Last Year: Jun25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Jun25
=194.268/1512.0626
=0.12847881

Shanxi C&Y Pharmaceutical Group Co's gearing of this year was 0.17307521. Shanxi C&Y Pharmaceutical Group Co's gearing of last year was 0.12847881. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun26)=Total Current Assets/Total Current Liabilities
=518.289/519.797
=0.99709887

Current Ratio (Last Year: Jun25)=Total Current Assets/Total Current Liabilities
=456.377/486.952
=0.93721147

Shanxi C&Y Pharmaceutical Group Co's current ratio of this year was 0.99709887. Shanxi C&Y Pharmaceutical Group Co's current ratio of last year was 0.93721147. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Shanxi C&Y Pharmaceutical Group Co's number of shares in issue this year was 247.895. Shanxi C&Y Pharmaceutical Group Co's number of shares in issue last year was 234.449. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=563.646/849.675
=0.66336658

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=555.776/818.49
=0.67902601

Shanxi C&Y Pharmaceutical Group Co's gross margin of this year was 0.66336658. Shanxi C&Y Pharmaceutical Group Co's gross margin of last year was 0.67902601. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun25)
=849.675/1496.381
=0.56781996

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun24)
=818.49/1505.502
=0.54366583

Shanxi C&Y Pharmaceutical Group Co's asset turnover of this year was 0.56781996. Shanxi C&Y Pharmaceutical Group Co's asset turnover of last year was 0.54366583. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+1+0+0+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shanxi C&Y Pharmaceutical Group Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Shanxi C&Y Pharmaceutical Group Co (SZSE:300254) has a Piotroski F-Score of 5 as of Aug. 25, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Shanxi C&Y Pharmaceutical Group Co and its competitors. This is near median its historical median of 5.00. Over the past decade, Shanxi C&Y Pharmaceutical Group Co's Piotroski F-Score has ranged from 2.00 to 8.00. According to the industry distribution chart, Shanxi C&Y Pharmaceutical Group Co ranks #390 out of 983 companies in the Drug Manufacturers industry, placing it in the top 39.7%.
Is Shanxi C&Y Pharmaceutical Group Co's Piotroski F-Score too high?
Shanxi C&Y Pharmaceutical Group Co's current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Shanxi C&Y Pharmaceutical Group Co's value of 5 is 0% at this industry median. Based on the distribution chart, Shanxi C&Y Pharmaceutical Group Co ranks #390 out of 983 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shanxi C&Y Pharmaceutical Group Co has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanxi C&Y Pharmaceutical Group Co's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shanxi C&Y Pharmaceutical Group Co ranks #390 out of 983 companies for Piotroski F-Score. This puts Shanxi C&Y Pharmaceutical Group Co in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Shanxi C&Y Pharmaceutical Group Co's value of 5 is 0% at this benchmark. Historically, Shanxi C&Y Pharmaceutical Group Co's own Piotroski F-Score has ranged from 2.00 to 8.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Shanxi C&Y Pharmaceutical Group Co has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanxi C&Y Pharmaceutical Group Co's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Shanxi C&Y Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanxi C&Y Pharmaceutical Group Co's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanxi C&Y Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Shanxi C&Y Pharmaceutical Group Co (SZSE:300254) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥12.40, compared to a current price of ¥9.32 — trading 24.8% below its estimated fair value. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 0% at the Drug Manufacturers industry median of 5.00. Shanxi C&Y Pharmaceutical Group Co's overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Shanxi C&Y Pharmaceutical Group Co (SZSE:300254), the current Piotroski F-Score is 5 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanxi C&Y Pharmaceutical Group Co (SZSE:300254) Overvalued in 2026?

Based on GuruFocus' analysis, Shanxi C&Y Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥9.32 is trading 24.8% below its estimated GF Value™ of ¥12.40. GuruFocus considers Shanxi C&Y Pharmaceutical Group Co to be Modestly Undervalued.

Key valuation signals for SZSE:300254:

  • Piotroski F-Score: 5 (near median its 10-year median of 5.00)
  • GF Value™: ¥12.40 vs. price of ¥9.32 (24.8% below fair value)
  • GF Score™: 47/100 with 6 warning signs
  • Industry Position: 0% at the Drug Manufacturers median (#390 of 983)

No single metric tells the full story. See the SZSE:300254 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shanxi C&Y Pharmaceutical Group Co Business Description

Address No.53, Hubin Street, Economic and Technological Development Zone, Datong, CHN, 037010
Shanxi C&Y Pharmaceutical Group Co Ltd is engaged in the production, research and development, and sales of pharmaceutical products. The company offers pregnancy products and services, anti-infective, and urinary health.
47GF Score

Get the complete analysis for SZSE:300254

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥9.32
Price
¥12.40
GF Value